Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST)

Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: a7fa07d80f3da7a6904b9b05f96f1cd118f76dfa
First added on: Feb 05, 2025